Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
Ian D. Davis(Austin Health), Jonathan Cebon(La Trobe University), Achim A. Jungbluth(Gynecologic Oncology Group), Eric W. Hoffman(Cornell University), Tsin Yee Tai(Cornell University), Simon Green(Endometriosis UK), Weisan Chen(La Trobe University), Nektaria Dimopoulos(Cornell University), Sue Sturrock(Cornell University), Gerd Ritter(Memorial Sloan Kettering Cancer Center), Grant A. McArthur(The University of Melbourne), Eugene Maraskovsky(Cornell University), Mark Shackleton(Australian Research Council), Lena Miloradovic(Cornell University), Andrew G. S. Cuthbertson(Cornell University), Sacha Gnjatic(Tisch Hospital), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), Duncan MacGregor(Cornell University), Tina Luke(Cornell University), Lloyd J. Old(Gynecologic Oncology Group), Qiyuan Chen(Cornell University), Heather Jackson(Cornell University), Darryl Maher(Cornell University), Susan V Mitchell(Cornell University), Roger Murphy(Cornell University), Phillip Parente(Cornell University), Yao-Tseng Chen(Cornell University), Wendie Hopkins(Cornell University)
Cited by 440
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k